263 results on '"Oze, I."'
Search Results
2. Association between incremental gains in the objective response rate and survival improvement in phase III trials of first-line chemotherapy for extensive disease small-cell lung cancer
- Author
-
Hotta, K., Kiura, K., Fujiwara, Y., Takigawa, N., Oze, I., Ochi, N., Tabata, M., and Tanimoto, M.
- Published
- 2009
- Full Text
- View/download PDF
3. Association between dietary folate intake and clinical outcome in head and neck squamous cell carcinoma
- Author
-
Kawakita, D., Matsuo, K., Sato, F., Oze, I., Hosono, S., Ito, H., Watanabe, M., Yatabe, Y., Hanai, N., Hasegawa, Y., Tajima, K., Murakami, S., and Tanaka, H.
- Published
- 2012
- Full Text
- View/download PDF
4. A randomized trial of sodium alginate prevention of radiation-induced esophagitis in patients with locally advanced NSCLC receiving concurrent chemoradiotherapy: OLCSG1401
- Author
-
Yokoyama, T., primary, Ninomiya, K., additional, Oze, I., additional, Hata, T., additional, Tanaka, A., additional, Bessho, A., additional, Hosokawa, S., additional, Kuyama, S., additional, Kudo, K., additional, Kozuki, T., additional, Harada, D., additional, Yasugi, M., additional, Murakami, T., additional, Nakanishi, M., additional, Takigawa, N., additional, Katsui, K., additional, Maeda, Y., additional, Hotta, K., additional, and Kiura, K., additional
- Published
- 2019
- Full Text
- View/download PDF
5. Randomized Phase II Study Comparing Mannitol with Furosemide for the Prevention of Renal Toxicity Induced by Cisplatin-based Chemotherapy with Short-term Low-volume Hydration in Advanced Non-small Cell Lung Cancer: The OLCSG1406 Study Protocol
- Author
-
Makimoto, G., Ichihara, E., Hotta, K., Ninomiya, K., Oze, I., Minami, D., Ninomiya, T., Kubo, T., Ohashi, K., Tabata, M., Maeda, Y., and Katsuyuki Kiura
- Subjects
Adult ,Lung Neoplasms ,Drinking ,Middle Aged ,Kidney ,lung cancer ,Clinical Protocols ,Furosemide ,Carcinoma, Non-Small-Cell Lung ,Humans ,Mannitol ,Prospective Studies ,Cisplatin ,Diuretics ,hydration ,non-small cell lung cancer ,Aged - Abstract
Although cisplatin-based chemotherapy shows a survival advantage compared to carboplatin for treating advanced non-small cell lung cancer, high-volume hydration and a long infusion time are necessary to avoid nephrotoxicity, and cisplatin-based chemotherapy has been difficult to administer in outpatient settings. A low-volume hydration method using mannitol or furosemide as forced diuresis was recently introduced, but there are no clear conclusions regarding which agent should be used. We describe our ongoing randomized phase II trial (the OLCSG1406 Study) evaluating the efficacy of forced diuresis. This study will clarify whether mannitol or furosemide is more suitable in cisplatin-based chemotherapy with low-volume hydration.
- Published
- 2018
6. P2.06-10 Combination Chemotherapy with Cisplatin, Pemetrexed, and Nivolumab for Malignant Pleural Mesothelioma: A Trial in Progress
- Author
-
Fujimoto, N., primary, Aoe, K., additional, Kozuki, T., additional, Oze, I., additional, Kato, K., additional, Kishimoto, T., additional, and Hotta, K., additional
- Published
- 2018
- Full Text
- View/download PDF
7. P2.01-034 Phase I/II Trial of Weekly Nab-Paclitaxel as 2nd or 3rd Line Treatment in NSCLC Without Driver Mutations. (OLCSG1303)
- Author
-
Kudo, K., primary, Kuyama, S., additional, Harada, D., additional, Kozuki, T., additional, Bessho, A., additional, Hotta, K., additional, Yoshioka, H., additional, Gemba, K., additional, Takigawa, N., additional, Oze, I., additional, and Kiura, K., additional
- Published
- 2017
- Full Text
- View/download PDF
8. Risk of second malignancies after definitive therapy for esophageal cancer: A competing risk analysis
- Author
-
Mitani, S., primary, Oze, I., additional, Kadowaki, S., additional, Masuishi, T., additional, Narita, Y., additional, Taniguchi, H., additional, Ura, T., additional, Ando, M., additional, Tajika, M., additional, Makita, C., additional, Kodaira, T., additional, Uemura, N., additional, Abe, T., additional, and Muro, K., additional
- Published
- 2017
- Full Text
- View/download PDF
9. Evaluation of quality of life in survivors with malignant pleural mesothelioma in Japan
- Author
-
Oze, I., primary, Nagamatsu, Y., additional, Aoe, K., additional, Hotta, K., additional, Kato, K., additional, Nakagawa, J., additional, Hara, K., additional, Kishimoto, T., additional, and Fujimoto, N., additional
- Published
- 2017
- Full Text
- View/download PDF
10. Phase I/II trial of weekly nab-paclitaxel as 2nd or 3rd line treatment in NSCLC without driver mutations. (OLCSG1303)
- Author
-
Ninomiya, T., primary, Hotta, K., additional, Ohashi, K., additional, Kubo, T., additional, Harada, D., additional, Kozuki, T., additional, Nogami, N., additional, Oze, I., additional, Hosokawa, S., additional, Bessho, A., additional, Yoshioka, H., additional, Kudo, K., additional, Kuyama, S., additional, Harita, S., additional, Takata, I., additional, Fujimoto, N., additional, Moritaka, T., additional, Ichikawa, H., additional, Takigawa, N., additional, and Kiura, K., additional
- Published
- 2017
- Full Text
- View/download PDF
11. 1807P - A randomized trial of sodium alginate prevention of radiation-induced esophagitis in patients with locally advanced NSCLC receiving concurrent chemoradiotherapy: OLCSG1401
- Author
-
Yokoyama, T., Ninomiya, K., Oze, I., Hata, T., Tanaka, A., Bessho, A., Hosokawa, S., Kuyama, S., Kudo, K., Kozuki, T., Harada, D., Yasugi, M., Murakami, T., Nakanishi, M., Takigawa, N., Katsui, K., Maeda, Y., Hotta, K., and Kiura, K.
- Published
- 2019
- Full Text
- View/download PDF
12. Chemoradiotherapy versus surgery for clinical stage I esophageal squamous cell carcinoma: A long-term comparison
- Author
-
Mitani, S., primary, Kadowaki, S., additional, Oze, I., additional, Masuishi, T., additional, Narita, Y., additional, Taniguchi, H., additional, Ura, T., additional, Ando, M., additional, Tajika, M., additional, Makita, C., additional, Kodaira, T., additional, Uemura, N., additional, Abe, T., additional, and Muro, K., additional
- Published
- 2016
- Full Text
- View/download PDF
13. 205P Development of nomograms including HER2 status for predicting survival in metastatic gastric cancer
- Author
-
Narita, Y., primary, Kadowaki, S., additional, Oze, I., additional, Taniguchi, H., additional, Ura, T., additional, Ando, M., additional, Ito, S., additional, Yatabe, Y., additional, Tajika, M., additional, and Muro, K., additional
- Published
- 2015
- Full Text
- View/download PDF
14. Optimal Food Consumption among Japanese Adults with Adequate Nutritional Intake According to the Dietary Reference Intakes for Japanese.
- Author
-
Imaeda, N., primary, Wakai, K., additional, Goto, C., additional, Kamano, S. K., additional, Nanri, H., additional, Hosono, S., additional, Oze, I., additional, Watanabe, M., additional, Fukuda, N., additional, Yamaguchi, M., additional, Nakamoto, M., additional, Nakahata, N. T., additional, Tanaka, H., additional, and Group, J. M. S., additional
- Published
- 2015
- Full Text
- View/download PDF
15. 1622P - Evaluation of quality of life in survivors with malignant pleural mesothelioma in Japan
- Author
-
Oze, I., Nagamatsu, Y., Aoe, K., Hotta, K., Kato, K., Nakagawa, J., Hara, K., Kishimoto, T., and Fujimoto, N.
- Published
- 2017
- Full Text
- View/download PDF
16. 1368P - Phase I/II trial of weekly nab-paclitaxel as 2nd or 3rd line treatment in NSCLC without driver mutations. (OLCSG1303)
- Author
-
Ninomiya, T., Hotta, K., Ohashi, K., Kubo, T., Harada, D., Kozuki, T., Nogami, N., Oze, I., Hosokawa, S., Bessho, A., Yoshioka, H., Kudo, K., Kuyama, S., Harita, S., Takata, I., Fujimoto, N., Moritaka, T., Ichikawa, H., Takigawa, N., and Kiura, K.
- Published
- 2017
- Full Text
- View/download PDF
17. 634P - Risk of second malignancies after definitive therapy for esophageal cancer: A competing risk analysis
- Author
-
Mitani, S., Oze, I., Kadowaki, S., Masuishi, T., Narita, Y., Taniguchi, H., Ura, T., Ando, M., Tajika, M., Makita, C., Kodaira, T., Uemura, N., Abe, T., and Muro, K.
- Published
- 2017
- Full Text
- View/download PDF
18. Comparison of Surgery with Definitive Chemoradiotherapy for Potentially Resectable Esophageal Cancer: a Propensity-Score Analysis
- Author
-
Nomura, M., primary, Abe, T., additional, Kodaira, T., additional, Oze, I., additional, Komori, A., additional, Narita, Y., additional, Masuishi, T., additional, Taniguchi, H., additional, Kadowaki, S., additional, Takahari, D., additional, Ura, T., additional, Andoh, M., additional, Kawai, R., additional, Uemura, N., additional, Tomita, N., additional, Tachibana, H., additional, Tanaka, T., additional, Tajika, M., additional, Niwa, Y., additional, and Muro, K., additional
- Published
- 2014
- Full Text
- View/download PDF
19. 671P - Chemoradiotherapy versus surgery for clinical stage I esophageal squamous cell carcinoma: A long-term comparison
- Author
-
Mitani, S., Kadowaki, S., Oze, I., Masuishi, T., Narita, Y., Taniguchi, H., Ura, T., Ando, M., Tajika, M., Makita, C., Kodaira, T., Uemura, N., Abe, T., and Muro, K.
- Published
- 2016
- Full Text
- View/download PDF
20. Randomised phase II study comparing dose-escalated weekly paclitaxel vs standard-dose weekly paclitaxel for patients with previously treated advanced gastric cancer
- Author
-
Shitara, K, primary, Yuki, S, additional, Tahahari, D, additional, Nakamura, M, additional, Kondo, C, additional, Tsuda, T, additional, Kii, T, additional, Tsuji, Y, additional, Utsunomiya, S, additional, Ichikawa, D, additional, Hosokawa, A, additional, Ishiguro, A, additional, Sakai, D, additional, Hironaka, S, additional, Oze, I, additional, Matsuo, K, additional, and Muro, K, additional
- Published
- 2013
- Full Text
- View/download PDF
21. Time to first cigarette and lung cancer risk in Japan
- Author
-
Ito, H., primary, Gallus, S., additional, Hosono, S., additional, Oze, I., additional, Fukumoto, K., additional, Yatabe, Y., additional, Hida, T., additional, Mitsudomi, T., additional, Negri, E., additional, Yokoi, K., additional, Tajima, K., additional, La Vecchia, C., additional, Tanaka, H., additional, and Matsuo, K., additional
- Published
- 2013
- Full Text
- View/download PDF
22. The aldehyde dehydrogenase 2 (ALDH2) Glu504Lys polymorphism interacts with alcohol drinking in the risk of stomach cancer
- Author
-
Matsuo, K., primary, Oze, I., additional, Hosono, S., additional, Ito, H., additional, Watanabe, M., additional, Ishioka, K., additional, Ito, S., additional, Tajika, M., additional, Yatabe, Y., additional, Niwa, Y., additional, Yamao, K., additional, Nakamura, S., additional, Tajima, K., additional, and Tanaka, H., additional
- Published
- 2013
- Full Text
- View/download PDF
23. Preliminary Safety Data from Randomized Phase II Study Comparing Dose-Escalated Weekly Paclitaxel Versus Standard-Dose Weekly Paclitaxel for Patients with Previously Treated Advanced Gastric Cancer
- Author
-
Nakamura, M., primary, Shitara, K., additional, Yuki, S., additional, Takahari, D., additional, Kondo, C., additional, Tsuda, T., additional, Kii, T., additional, Tsuji, Y., additional, Ichikawa, D., additional, Utsunomiya, S., additional, Hosokawa, A., additional, Ishiguro, A., additional, Oze, I., additional, and Muro, K., additional
- Published
- 2012
- Full Text
- View/download PDF
24. Preliminary Safety Data from a Randomized Phase II Study Comparing Dose-Escalated weekly Paclitaxel versus Standard-dose weekly Paclitaxel for Patients with Previously Treated advanced Gastric Cancer
- Author
-
Yuki, S., primary, Shitara, K., additional, Takahari, D., additional, Nakamura, M., additional, Kondo, C., additional, Tsuda, T., additional, Kii, T., additional, Tsuji, Y., additional, Oze, I., additional, and Muro, K., additional
- Published
- 2012
- Full Text
- View/download PDF
25. Time trend in treatment-related deaths of patients with small cell lung cancer (SCLC) enrolled into phase III trials of systemic treatment.
- Author
-
Fujiwara, Y., primary, Hotta, K., additional, Kiura, K., additional, Ochi, N., additional, Takigawa, N., additional, Oze, I., additional, Ichihara, E., additional, Tabata, M., additional, and Tanimoto, M., additional
- Published
- 2011
- Full Text
- View/download PDF
26. Randomized Phase II Study Comparing Dose Escalated Weekly Paclitaxel vs. Standard Dose Weekly Paclitaxel for Patients with Previously Treated Advanced Gastric Cancer
- Author
-
Shitara, K., primary, Oze, I., additional, Mizota, A., additional, Kondo, C., additional, Nomura, M., additional, Yokota, T., additional, Takahari, D., additional, Ura, T., additional, Yuki, S., additional, Komatsu, Y., additional, Matsuo, K., additional, and Muro, K., additional
- Published
- 2010
- Full Text
- View/download PDF
27. Impact of smoking on lung cancer risk is stronger in those with the homozygous aldehyde dehydrogenase 2 null allele in a Japanese population
- Author
-
Park, J. Y., primary, Matsuo, K., additional, Suzuki, T., additional, Ito, H., additional, Hosono, S., additional, Kawase, T., additional, Watanabe, M., additional, Oze, I., additional, Hida, T., additional, Yatabe, Y., additional, Mitsudomi, T., additional, Takezaki, T., additional, Tajima, K., additional, and Tanaka, H., additional
- Published
- 2010
- Full Text
- View/download PDF
28. Results of 27 years of phase III trials for patients with extensive-disease small-cell lung cancer
- Author
-
Oze, I., primary, Kiura, K., additional, Hotta, K., additional, Ochi, N., additional, Fujiwara, Y., additional, Takigawa, N., additional, Tabata, M., additional, Shinkai, T., additional, and Tanimoto, M., additional
- Published
- 2009
- Full Text
- View/download PDF
29. Prognostic implication of smoking history in patients with non-small cell lung cancer (NSCLC)
- Author
-
Oze, I., primary, Segawa, Y., additional, Nogami, N., additional, Komori, E., additional, Sawada, S., additional, Yamashita, M., additional, and Shinkai, T., additional
- Published
- 2007
- Full Text
- View/download PDF
30. 633P - Comparison of Surgery with Definitive Chemoradiotherapy for Potentially Resectable Esophageal Cancer: a Propensity-Score Analysis
- Author
-
Nomura, M., Abe, T., Kodaira, T., Oze, I., Komori, A., Narita, Y., Masuishi, T., Taniguchi, H., Kadowaki, S., Takahari, D., Ura, T., Andoh, M., Kawai, R., Uemura, N., Tomita, N., Tachibana, H., Tanaka, T., Tajika, M., Niwa, Y., and Muro, K.
- Published
- 2014
- Full Text
- View/download PDF
31. Randomised phase II study comparing dose-escalated weekly paclitaxel vs standard-dose weekly paclitaxel for patients with previously treated advanced gastric cancer.
- Author
-
Shitara, K, Yuki, S, Tahahari, D, Nakamura, M, Kondo, C, Tsuda, T, Kii, T, Tsuji, Y, Utsunomiya, S, Ichikawa, D, Hosokawa, A, Ishiguro, A, Sakai, D, Hironaka, S, Oze, I, Matsuo, K, and Muro, K
- Subjects
STOMACH cancer treatment ,PACLITAXEL ,DRUG dosage ,COMPARATIVE studies ,PHARMACOLOGY ,CLINICAL drug trials - Abstract
Background:This randomised phase II trial compared dose-escalated weekly paclitaxel (wPTX) vs standard-dose wPTX for patients with previously treated advanced gastric cancer (AGC).Methods:Ninety patients were randomised to a standard dose of wPTX (80 mg m
−2 ) or an escalated dose of wPTX (80-120 mg m−2 ) to assess the superiority of overall survival (OS) with a one-sided alpha error of 0.3 and a power of 0.8.Results:The median OS showed a trend towards longer survival in the dose-escalated arm (11.8 vs 9.6 months; hazard ratio (HR), 0.75; one-sided P=0.12), although it was statistically not significant. The median progression-free survival (PFS) was significantly longer in the dose-escalated arm (4.3 vs 2.5 months, HR, 0.55; P=0.017). Objective response rate was 30.3% with dose escalation and 17.1% with standard dose (P=0.2). The frequency of all grades of neutropenia was significantly higher with dose escalation (88.7% vs 60.0%, P=0.002); however, no significant difference was observed in the proportion of patients experiencing grade 3 or more (40.9% vs 31.1%, P=0.34).Conclusion:Dose-escalated wPTX in patients with pretreated AGC met our predefined threshold of primary end point, OS (P<0.3); however, it did not show a significantly longer OS. Progression-free survival was significantly better with dose escalation. [ABSTRACT FROM AUTHOR]- Published
- 2014
- Full Text
- View/download PDF
32. Impact of smoking status on clinical outcome in oral cavity cancer patients.
- Author
-
Kawakita D, Hosono S, Ito H, Oze I, Watanabe M, Hanai N, Hasegawa Y, Tajima K, Murakami S, Tanaka H, and Matsuo K
- Abstract
The association between smoking status and survival in oral cavity squamous cell carcinoma (OSCC) patients remains unclear. Therefore, we evaluated the association between smoking status before treatment and clinical outcome in OSCC patients. We conducted a retrospective cohort study of 222 OSCC patients who were treated at Aichi Cancer Center in Japan. Of these, 82 patients (36.9%) were non-smokers, 65 (29.3%) were light smokers (pack-years smoking (PY) <30), 54 (24.3%) were moderate smokers (30PY<60), and 21 (9.5%) were heavy smokers (60PY). The survival impact of pre-treatment smoking status was evaluated using multivariate proportional hazard models. Five-year overall survival for non-, light, moderate, and heavy smokers was 72.9% (95% confidence interval CI): (61.4-81.5), 85.5% (74.0-92.2), 59.9% (44.3-72.4) and 69.0% (42.8-85.0). Adjusted hazard ratios (HRs) for moderate and heavy smokers in comparison with light smokers were 2.44 (1.07-5.57, P=0.034) and 2.66 (0.97-7.33, P=0.058) and the dose-response relationship among smokers was statistically significance (P(trend)=0.024). In addition, adjusted HR for non-smokers relative to light smokers was 2.27 (0.84-6.15, P=0.108). We observed a suggestive heterogeneity in the impact of smoking status by treatment method (P for heterogeneity=0.069). Effect of smoking was evident only among the chemoradiotherapy or radiotherapy group. In this study, we found the significant positive dose-response relationship among smokers on clinical outcome in OSCC patients and that non-smokers were worse prognosis than light smokers. In addition, this effect might differ by treatment method. [ABSTRACT FROM AUTHOR]
- Published
- 2012
33. Association of BMI, smoking, and alcohol with multiple myeloma mortality in Asians: A pooled analysis of more than 800,000 participants in the Asia cohort Consortium
- Author
-
Keun-Young Yoo, Hui Cai, Seiki Kanemura, Tomotaka Ugai, Hidemi Ito, Keitaro Matsuo, Yumi Sugawara, Yong-Bing Xiang, Woon-Puay Koh, Shafiur Rahman, Kee Seng Chia, John D. Potter, San Lin You, Shoichiro Tsugane, Ichiro Tsuji, Wei Zheng, Keiko Wada, Prakash C. Gupta, Yu-Tang Gao, Manami Inoue, Sue K. Park, Atsuko Sadakane, Paolo Boffetta, Norie Sawada, Akiko Tamakoshi, Kotaro Ozasa, Daehee Kang, Mangesh S. Pednekar, Chisato Nagata, Chien-Jen Chen, Habibul Ahsan, Yasutake Tomata, Eiko Saito, Isao Oze, Xiao-Ou Shu, Jian-Min Yuan, Ugai T., Ito H., Oze I., Saito E., Rahman M.S., Boffetta P., Gupta P.C., Sawada N., Tamakoshi A., Shu X.O., Koh W.-P., Gao Y.-T., Sadakane A., Tsuji I., Park S.K., Nagata C., You S.-L., Pednekar M.S., Tsugane S., Cai H., Yuan J.-M., Xiang Y.-B., Ozasa K., Tomata Y., Kanemura S., Sugawara Y., Wada K., Chen C.-J., Yoo K.-Y., Chia K.S., Ahsan H., Zheng W., Inoue M., Kang D., Potter J., and Matsuo K.
- Subjects
Adult ,Male ,0301 basic medicine ,Asia ,Adolescent ,Alcohol Drinking ,Epidemiology ,Alcohol ,Article ,Body Mass Index ,Cohort Studies ,Young Adult ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,medicine ,Humans ,Multiple myeloma ,Proportional hazards model ,business.industry ,Smoking ,medicine.disease ,Confidence interval ,multiple myeloma ,030104 developmental biology ,Pooled analysis ,Increased risk ,Oncology ,chemistry ,030220 oncology & carcinogenesis ,Cohort ,Female ,business ,Body mass index ,Demography - Abstract
Background: To date, few epidemiologic studies have been conducted to elucidate lifestyle-related risk factors for multiple myeloma in Asia. We investigated the association of body mass index (BMI), smoking, and alcohol intake with the risk of multiple myeloma mortality through a pooled analysis of more than 800,000 participants in the Asia Cohort Consortium. Methods: The analysis included 805,309 participants contributing 10,221,623 person-years of accumulated follow-up across Asia Cohort Consortium cohorts. HRs and 95% confidence intervals (95% CI) for the association between BMI, smoking, and alcohol at baseline and the risk of multiple myeloma mortality were assessed using a Cox proportional hazards model with shared frailty. Results: We observed a statistically significant dose-dependent association between BMI categories and the risk of multiple myeloma mortality ( Conclusions: This study showed that excess body mass is associated with an increased risk of multiple myeloma mortality among Asian populations. In contrast, our results do not support an association between smoking or alcohol consumption and the risk of multiple myeloma mortality in Asian populations. Impact: This study provides important evidence on the association of BMI, smoking, and alcohol with the risk of multiple myeloma mortality in Asian populations.
- Published
- 2019
34. Associations of Body Mass Index, Smoking, and Alcohol Consumption With Prostate Cancer Mortality in the Asia Cohort Consortium
- Author
-
Ichiro Tsuji, Norie Sawada, Waka Ohishi, Betsy Rolland, Daehee Kang, Yoshikazu Nishino, Kotaro Ozasa, Chien-Jen Chen, Shao Yuan Chuang, Habibul Ahsan, Jung Eun Lee, Mangesh S. Pednekar, Masako Kakizaki, Dongfeng Gu, Lesley M. Butler, Prakash C. Gupta, Shoichiro Tsugane, Paolo Boffetta, San Lin You, Wei Zheng, Rashmi Sinha, Yu Chen, Hideo Tanaka, Yong-Bing Xiang, Jiang He, Dong Hyun Kim, Dale McLerran, Keun-Young Yoo, Mark D. Thornquist, Ziding Feng, Yumi Sugawara, Jay H. Fowke, Wen-Harn Pan, Manami Inoue, Sue K. Park, Faruque Parvez, Akiko Tamakoshi, Renwei Wang, Kunnambath Ramadas, John D. Potter, Woon-Puay Koh, Eric J. Grant, Yoon Ok Ahn, Isao Oze, Yasutake Tomata, Xiao-Ou Shu, Catherine Sauvaget, Jian-Min Yuan, Fowke, J.H., McLerran, D.F., Gupta, P.C., He, J., Shu, X.-O., Ramadas, K., Tsugane, S., Inoue, M., Tamakoshi, A., Koh, W.-P., Nishino, Y., Tsuji, I., Ozasa, K., Yuan, J.-M., Tanaka, H., Ahn, Y.-O., Chen, C.-J., Sugawara, Y., Yoo, K.-Y., Ahsan, H., Pan, W.-H., Pednekar, M., Gu, D., Xiang, Y.-B., Sauvaget, C., Sawada, N., Wang, R., Kakizaki, M., Tomata, Y., Ohishi, W., Butler, L.M., Oze, I., Kim, D.-H., You, S.-L., Park, S.K., Parvez, F., Chuang, S.-Y., Chen, Y., Lee, J.E., Grant, E., Rolland, B., Thornquist, M., Feng, Z., Zheng, W., Boffetta, P., Sinha, R., Kang, D., and Potter, J.D.
- Subjects
Gynecology ,Male ,medicine.medical_specialty ,Alcohol Drinking ,Epidemiology ,business.industry ,Original Contributions ,Hazard ratio ,Smoking ,Prostatic Neoplasms ,medicine.disease ,Body Mass Index ,Prostate-specific antigen ,Prostate cancer ,Prostate cancer screening ,Cohort ,Medicine ,Humans ,Obesity ,business ,Prospective cohort study ,Body mass index ,Demography ,Cause of death ,Prostate cancer - body mass - alcohol consumption - Abstract
Many potentially modifiable risk factors for prostate cancer are also associated with prostate cancer screening, which may induce a bias in epidemiologic studies. We investigated the associations of body mass index (weight (kg)/height (m)2), smoking, and alcohol consumption with risk of fatal prostate cancer in Asian countries where prostate cancer screening is not widely utilized. Analysis included 18 prospective cohort studies conducted during 1963-2006 across 6 countries in southern and eastern Asia that are part of the Asia Cohort Consortium. Body mass index, smoking, and alcohol intake were determined by questionnaire at baseline, and cause of death was ascertained through death certificates. Analysis included 522,736 men aged 54 years, on average, at baseline. During 4.8 million person-years of follow-up, there were 634 prostate cancer deaths (367 prostate cancer deaths across the 11 cohorts with alcohol data). In Cox proportional hazards analyses of all cohorts in the Asia Cohort Consortium, prostate cancer mortality was not significantly associated with obesity (body mass index >25: hazard ratio (HR) = 1.08, 95% confidence interval (CI): 0.85, 1.36), ever smoking (HR = 1.00, 95% CI: 0.84, 1.21), or heavy alcohol intake (HR = 1.00, 95% CI: 0.74, 1.35). Differences in prostate cancer screening and detection probably contribute to differences in the association of obesity, smoking, or alcohol intake with prostate cancer risk and mortality between Asian and Western populations and thus require further investigation. © The Author 2015. Published by Oxford University Press on behalf of the Johns Hopkins Bloomberg School of Public Health.
- Published
- 2015
35. Burden of Total and Cause-Specific Mortality Related to Tobacco Smoking among Adults Aged ≥45 Years in Asia: A Pooled Analysis of 21 Cohorts
- Author
-
Betsy Rolland, Hideo Tanaka, Eric J. Grant, Akiko Tamakoshi, Chien-Jen Chen, Masako Kakizaki, Yoon Ok Ahn, Lesley M. Butler, Yong-Bing Xiang, Paolo Boffetta, Mark D. Thornquist, Dale McLerran, San Lin You, Yu Chen, Fujiko Irie, Daehee Kang, Keitaro Matsuo, Rashmi Sinha, Shao Yuan Chuang, Waka Ohishi, Toshimi Sairenchi, Woon-Puay Koh, Ichiro Tsuji, Norie Sawada, Dong Hyun Kim, Zhenming Fu, Mangesh S. Pednekar, Takashi Watanabe, You-Lin Qiao, Prakash C. Gupta, Renwei Wang, Gong Yang, Jin-Hu Fan, Ziding Feng, Keun-Young Yoo, Jung Eun Lee, Sue K. Park, Wei Zheng, Jiang He, Yumi Sugawara, Wen-Harn Pan, Yu-Tang Gao, John D. Potter, Kunnambath Ramadas, Yoshikazu Nishino, Shoichiro Tsugane, Faruque Parvez, Isao Oze, Xiao-Ou Shu, Catherine Sauvaget, Jian-Min Yuan, Manami Inoue, Chen-Yang Shen, Dongfeng Gu, Kotaro Ozasa, Habibul Ahsan, International Prevention Research Institute (IPRI), The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai [New York] (MSSM), Zheng, W., McLerran, D.F., Rolland, B.A., Fu, Z., Boffetta, P., He, J., Gupta, P.C., Ramadas, K., Tsugane, S., Irie, F., Tamakoshi, A., Gao, Y.-T., Koh, W.-P., Shu, X.-O., Ozasa, K., Nishino, Y., Tsuji, I., Tanaka, H., Chen, C.-J., Yuan, J.-M., Ahn, Y.-O., Yoo, K.-Y., Ahsan, H., Pan, W.-H., Qiao, Y.-L., Gu, D., Pednekar, M.S., Sauvaget, C., Sawada, N., Sairenchi, T., Yang, G., Wang, R., Xiang, Y.-B., Ohishi, W., Kakizaki, M., Watanabe, T., Oze, I., You, S.-L., Sugawara, Y., Butler, L.M., Kim, D.-H., Park, S.K., Parvez, F., Chuang, S.-Y., Fan, J.-H., Shen, C.-Y., Chen, Y., Grant, E.J., Lee, J.E., Sinha, R., Matsuo, K., Thornquist, M., Inoue, M., Feng, Z., Kang, D., and Potter, J.D.
- Subjects
Adult ,Male ,Risk ,medicine.medical_specialty ,Asia ,Epidemiology ,Respiratory Tract Diseases ,Environmental Epidemiology ,Cost of Illness ,Risk Factors ,cardiovascular disease ,Neoplasms ,Environmental health ,Medicine and Health Sciences ,Prevalence ,Risk of mortality ,Humans ,cancer ,Medicine ,East Asia ,Risk factor ,Lung cancer ,respiratory diseases ,business.industry ,Public health ,Smoking ,Hazard ratio ,Tobacco control ,1. No poverty ,General Medicine ,Middle Aged ,medicine.disease ,Tobacco smoking ,3. Good health ,Cardiovascular Diseases ,Female ,[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie ,business ,Research Article - Abstract
Wei Zheng and colleagues quantify the burden of tobacco-smoking-related deaths for adults in Asia. Please see later in the article for the Editors' Summary, Background Tobacco smoking is a major risk factor for many diseases. We sought to quantify the burden of tobacco-smoking-related deaths in Asia, in parts of which men's smoking prevalence is among the world's highest. Methods and Findings We performed pooled analyses of data from 1,049,929 participants in 21 cohorts in Asia to quantify the risks of total and cause-specific mortality associated with tobacco smoking using adjusted hazard ratios and their 95% confidence intervals. We then estimated smoking-related deaths among adults aged ≥45 y in 2004 in Bangladesh, India, mainland China, Japan, Republic of Korea, Singapore, and Taiwan—accounting for ∼71% of Asia's total population. An approximately 1.44-fold (95% CI = 1.37–1.51) and 1.48-fold (1.38–1.58) elevated risk of death from any cause was found in male and female ever-smokers, respectively. In 2004, active tobacco smoking accounted for approximately 15.8% (95% CI = 14.3%–17.2%) and 3.3% (2.6%–4.0%) of deaths, respectively, in men and women aged ≥45 y in the seven countries/regions combined, with a total number of estimated deaths of ∼1,575,500 (95% CI = 1,398,000–1,744,700). Among men, approximately 11.4%, 30.5%, and 19.8% of deaths due to cardiovascular diseases, cancer, and respiratory diseases, respectively, were attributable to tobacco smoking. Corresponding proportions for East Asian women were 3.7%, 4.6%, and 1.7%, respectively. The strongest association with tobacco smoking was found for lung cancer: a 3- to 4-fold elevated risk, accounting for 60.5% and 16.7% of lung cancer deaths, respectively, in Asian men and East Asian women aged ≥45 y. Conclusions Tobacco smoking is associated with a substantially elevated risk of mortality, accounting for approximately 2 million deaths in adults aged ≥45 y throughout Asia in 2004. It is likely that smoking-related deaths in Asia will continue to rise over the next few decades if no effective smoking control programs are implemented. Please see later in the article for the Editors' Summary, Editors' Summary Background Every year, more than 5 million smokers die from tobacco-related diseases. Tobacco smoking is a major risk factor for cardiovascular disease (conditions that affect the heart and the circulation), respiratory disease (conditions that affect breathing), lung cancer, and several other types of cancer. All told, tobacco smoking kills up to half its users. The ongoing global “epidemic” of tobacco smoking and tobacco-related diseases initially affected people living in the US and other Western countries, where the prevalence of smoking (the proportion of the population that smokes) in men began to rise in the early 1900s, peaking in the 1960s. A similar epidemic occurred in women about 40 years later. Smoking-related deaths began to increase in the second half of the 20th century, and by the 1990s, tobacco smoking accounted for a third of all deaths and about half of cancer deaths among men in the US and other Western countries. More recently, increased awareness of the risks of smoking and the introduction of various tobacco control measures has led to a steady decline in tobacco use and in smoking-related diseases in many developed countries. Why Was This Study Done? Unfortunately, less well-developed tobacco control programs, inadequate public awareness of smoking risks, and tobacco company marketing have recently led to sharp increases in the prevalence of smoking in many low- and middle-income countries, particularly in Asia. More than 50% of men in many Asian countries are now smokers, about twice the prevalence in many Western countries, and more women in some Asian countries are smoking than previously. More than half of the world's billion smokers now live in Asia. However, little is known about the burden of tobacco-related mortality (deaths) in this region. In this study, the researchers quantify the risk of total and cause-specific mortality associated with tobacco use among adults aged 45 years or older by undertaking a pooled statistical analysis of data collected from 21 Asian cohorts (groups) about their smoking history and health. What Did the Researchers Do and Find? For their study, the researchers used data from more than 1 million participants enrolled in studies undertaken in Bangladesh, India, mainland China, Japan, the Republic of Korea, Singapore, and Taiwan (which together account for 71% of Asia's total population). Smoking prevalences among male and female participants were 65.1% and 7.1%, respectively. Compared with never-smokers, ever-smokers had a higher risk of death from any cause in pooled analyses of all the cohorts (adjusted hazard ratios [HRs] of 1.44 and 1.48 for men and women, respectively; an adjusted HR indicates how often an event occurs in one group compared to another group after adjustment for other characteristics that affect an individual's risk of the event). Compared with never smoking, ever smoking was associated with a higher risk of death due to cardiovascular disease, cancer (particularly lung cancer), and respiratory disease among Asian men and among East Asian women. Moreover, the researchers estimate that, in the countries included in this study, tobacco smoking accounted for 15.8% of all deaths among men and 3.3% of deaths among women in 2004—a total of about 1.5 million deaths, which scales up to 2 million deaths for the population of the whole of Asia. Notably, in 2004, tobacco smoking accounted for 60.5% of lung-cancer deaths among Asian men and 16.7% of lung-cancer deaths among East Asian women. What Do These Findings Mean? These findings provide strong evidence that tobacco smoking is associated with a substantially raised risk of death among adults aged 45 years or older throughout Asia. The association between smoking and mortality risk in Asia reported here is weaker than that previously reported for Western countries, possibly because widespread tobacco smoking started several decades later in most Asian countries than in Europe and North America and the deleterious effects of smoking take some years to become evident. The researchers note that certain limitations of their analysis are likely to affect the accuracy of its findings. For example, because no data were available to estimate the impact of secondhand smoke, the estimate of deaths attributable to smoking is likely to be an underestimate. However, the finding that nearly 45% of the global deaths from active tobacco smoking occur in Asia highlights the urgent need to implement comprehensive tobacco control programs in Asia to reduce the burden of tobacco-related disease. Additional Information Please access these websites via the online version of this summary at http://dx.doi.org/10.1371/journal.pmed.1001631. The World Health Organization provides information about the dangers of tobacco (in several languages) and about the WHO Framework Convention on Tobacco Control, an international instrument for tobacco control that came into force in February 2005 and requires parties to implement a set of core tobacco control provisions including legislation to ban tobacco advertising and to increase tobacco taxes; its 2013 report on the global tobacco epidemic is available The US Centers for Disease Control and Prevention provides detailed information about all aspects of smoking and tobacco use The UK National Health Services Choices website provides information about the health risks associated with smoking MedlinePlus has links to further information about the dangers of smoking (in English and Spanish) SmokeFree, a website provided by the UK National Health Service, offers advice on quitting smoking and includes personal stories from people who have stopped smoking Smokefree.gov, from the US National Cancer Institute, offers online tools and resources to help people quit smoking
- Published
- 2014
36. A Century of Change: Unraveling the Impact of Socioeconomic/Historical Milestones on Age at Menarche and Other Female Reproductive Factors in Japan.
- Author
-
Iwase M, Taniyama Y, Koyanagi YN, Kasugai Y, Oze I, Masuda N, Ito H, and Matsuo K
- Subjects
- Humans, Japan, Female, Adolescent, Retrospective Studies, Age Factors, Child, History, 20th Century, Adult, Middle Aged, Young Adult, Parity, Menarche, Socioeconomic Factors
- Abstract
Background: Reproductive factors, such as age at menarche, are known to be associated with disease risk, but data on trends in these factors in Japan are limited. In this study, we investigated secular trends in reproductive factors and explored their potential association with socioeconomic and historical events., Methods: We conducted a retrospective analysis of 62,005 Japanese women born between 1890 and 1991 using a survey conducted over 25 years. Trends in reproductive factors were analyzed using linear and joinpoint regression models, and their associations with major historical events involving Japan were evaluated., Results: We found that the age at menarche showed a significant downward trend (P < 0.001) over the century. Three joinpoints were identified, in 1932 (15.23 years old), 1946 (13.48 years old), and 1959 (12.71 years old), which indicated that average age at menarche decreased by approximately 0.8% per year between 1932 and 1946, and then by 0.4% per year between 1946 and 1959, both of which were statistically significant. However, after 1959, age of menarche remained stable. Analyses of other reproductive factors found significant changes, including a decrease in parity and the number of babies breastfed, and an increase in age at first birth., Conclusion: Age at menarche showed a long-term downward trend in Japan, with significant change points in annual percent change. Other factors showed secular changes in trends as well. These change points were observed at the same time as historical events, namely wars and economic development, suggesting that socioeconomic and environmental changes at the population level affect reproductive factors in females.
- Published
- 2024
- Full Text
- View/download PDF
37. Family history and gastric cancer incidence and mortality in Asia: a pooled analysis of more than half a million participants.
- Author
-
Huang D, Song M, Abe SK, Rahman MS, Islam MR, Saito E, De la Torre K, Sawada N, Tamakoshi A, Shu XO, Cai H, Hozawa A, Kanemura S, Kim J, Chen Y, Ito H, Sugawara Y, Park SK, Shin MH, Hirabayashi M, Kimura T, Gao YT, Wen W, Oze I, Shin A, Ahn YO, Ahsan H, Boffetta P, Chia KS, Matsuo K, Qiao YL, Rothman N, Zheng W, Inoue M, and Kang D
- Subjects
- Humans, Male, Female, Incidence, Asia epidemiology, Prospective Studies, Middle Aged, Risk Factors, Aged, Adult, Follow-Up Studies, Genetic Predisposition to Disease, Stomach Neoplasms mortality, Stomach Neoplasms epidemiology, Stomach Neoplasms genetics
- Abstract
Background: The family history of gastric cancer holds important implications for cancer surveillance and prevention, yet existing evidence predominantly comes from case-control studies. We aimed to investigate the association between family history of gastric cancer and gastric cancer risk overall and by various subtypes in Asians in a prospective study., Methods: We included 12 prospective cohorts with 550,508 participants in the Asia Cohort Consortium. Cox proportional hazard regression was used to estimate study-specific adjusted hazard ratios (HRs) and 95% confidence intervals (CIs) for the association between family history of gastric cancer and gastric cancer incidence and mortality, then pooled using random-effects meta-analyses. Stratified analyses were performed for the anatomical subsites and histological subtypes., Results: During the mean follow-up of 15.6 years, 2258 incident gastric cancers and 5194 gastric cancer deaths occurred. The risk of incident gastric cancer was higher in individuals with a family history of gastric cancer (HR 1.44, 95% CI 1.32-1.58), similarly in males (1.44, 1.31-1.59) and females (1.45, 1.23-1.70). Family history of gastric cancer was associated with both cardia (HR 1.26, 95% CI 1.00-1.60) and non-cardia subsites (1.49, 1.35-1.65), and with intestinal- (1.48, 1.30-1.70) and diffuse-type (1.59, 1.35-1.87) gastric cancer incidence. Positive associations were also found for gastric cancer mortality (HR 1.30, 95% CI 1.19-1.41)., Conclusions: In this largest prospective study to date on family history and gastric cancer, a familial background of gastric cancer increased the risk of gastric cancer in the Asian population. Targeted education, screening, and intervention in these high-risk groups may reduce the burden of gastric cancer., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
38. Association Between Awareness of Limiting Food Intake and All-cause Mortality: A Cohort Study in Japan.
- Author
-
Nishimoto D, Ibusuki R, Shimoshikiryo I, Shibuya K, Tanoue S, Koriyama C, Takezaki T, Oze I, Ito H, Hishida A, Tamura T, Kato Y, Tamada Y, Nishida Y, Shimanoe C, Suzuki S, Nishiyama T, Ozaki E, Tomida S, Kuriki K, Miyagawa N, Kondo K, Arisawa K, Watanabe T, Ikezaki H, Otonari J, Wakai K, and Matsuo K
- Subjects
- Humans, Middle Aged, Female, Japan epidemiology, Male, Adult, Aged, Cohort Studies, Health Knowledge, Attitudes, Practice, Eating, Cause of Death, Energy Intake, Mortality trends
- Abstract
Background: Improving diets requires an awareness of the need to limit foods for which excessive consumption is a health problem. Since there are limited reports on the link between this awareness and mortality risk, we examined the association between awareness of limiting food intake (energy, fat, and sweets) and all-cause mortality in a Japanese cohort study., Methods: Participants comprised 58,772 residents (27,294 men; 31,478 women) aged 35-69 years who completed baseline surveys of the Japan Multi-Institutional Collaborative Cohort Study from 2004 to 2014. Hazard ratios (HRs) for all-cause mortality and 95% confidence intervals (CIs) were estimated by sex using a Cox proportional hazard model, with adjustment for related factors. Mediation analysis with fat intake as a mediator was also conducted., Results: The mean follow-up period was 11 years, and 2,516 people died. Estimated energy and fat intakes according to the Food Frequency Questionnaire were lower in those with awareness of limiting food intake than in those without this awareness. Women with awareness of limiting fat intake showed a significant decrease in mortality risk (HR 0.73; 95% CI, 0.55-0.94). Mediation analysis revealed that this association was due to the direct effect of the awareness of limiting fat intake and that the total effect was not mediated by actual fat intake. Awareness of limiting energy or sweets intake was not related to mortality risk reduction., Conclusion: Awareness of limiting food intake had a limited effect on reducing all-cause mortality risk.
- Published
- 2024
- Full Text
- View/download PDF
39. Diabetes and gastric cancer incidence and mortality in the Asia Cohort Consortium: A pooled analysis of more than a half million participants.
- Author
-
De la Torre K, Song M, Abe SK, Rahman MS, Islam MR, Saito E, Min S, Huang D, Chen Y, Gupta PC, Sawada N, Tamakoshi A, Shu XO, Wen W, Sakata R, Kim J, Nagata C, Ito H, Park SK, Shin MH, Pednekar MS, Tsugane S, Kimura T, Gao YT, Cai H, Wada K, Oze I, Shin A, Ahn YO, Ahsan H, Boffetta P, Chia KS, Matsuo K, Qiao YL, Rothman N, Zheng W, Inoue M, and Kang D
- Subjects
- Humans, Incidence, Male, Female, Asia epidemiology, Middle Aged, Risk Factors, Prospective Studies, Cohort Studies, Aged, Adult, Stomach Neoplasms epidemiology, Stomach Neoplasms mortality, Stomach Neoplasms pathology, Diabetes Mellitus epidemiology, Diabetes Mellitus mortality
- Abstract
Background: Evidence suggests a possible link between diabetes and gastric cancer risk, but the findings remain inconclusive, with limited studies in the Asian population. We aimed to assess the impact of diabetes and diabetes duration on the development of gastric cancer overall, by anatomical and histological subtypes., Methods: A pooled analysis was conducted using 12 prospective studies included in the Asia Cohort Consortium. Among 558 981 participants (median age 52), after a median follow-up of 14.9 years and 10.5 years, 8556 incident primary gastric cancers and 8058 gastric cancer deaths occurred, respectively. Cox proportional hazard regression models were used to estimate study-specific hazard ratios (HRs) and 95% confidence intervals (CIs) and pooled using random-effects meta-analyses., Results: Diabetes was associated with an increased incidence of overall gastric cancer (HR 1.15, 95% CI 1.06-1.25). The risk association did not differ significantly by sex (women vs men: HR 1.31, 95% CI 1.07-1.60 vs 1.12, 1.01-1.23), anatomical subsites (noncardia vs cardia: 1.14, 1.02-1.28 vs 1.17, 0.77-1.78) and histological subtypes (intestinal vs diffuse: 1.22, 1.02-1.46 vs 1.00, 0.62-1.61). Gastric cancer risk increased significantly during the first decade following diabetes diagnosis (HR 4.70, 95% CI 3.77-5.86), and decreased with time (nonlinear p < .01). Positive associations between diabetes and gastric cancer mortality were observed (HR 1.15, 95% CI 1.03-1.28) but attenuated after a 2-year time lag., Conclusion: Diabetes was associated with an increased gastric cancer incidence regardless of sex, anatomical subsite, or subtypes of gastric cancer. The risk of gastric cancer was particularly high during the first decade following diabetes diagnosis., (© 2024 The Authors. Journal of Diabetes published by Ruijin Hospital, Shanghai Jiaotong University School of Medicine and John Wiley & Sons Australia, Ltd.)
- Published
- 2024
- Full Text
- View/download PDF
40. Diabetes is associated with increased liver cancer incidence and mortality in adults: A report from Asia Cohort Consortium.
- Author
-
Ho NT, Abe SK, Rahman MS, Islam R, Saito E, Gupta PC, Pednekar MS, Sawada N, Tsugane S, Tamakoshi A, Kimura T, Shu XO, Gao YT, Koh WP, Cai H, Wen W, Sakata R, Tsuji I, Malekzadeh R, Pourshams A, Kanemura S, Kim J, Chen Y, Ito H, Oze I, Nagata C, Wada K, Sugawara Y, Park SK, Shin A, Yuan JM, Wang R, Kweon SS, Shin MH, Poustchi H, Vardanjani HM, Ahsan H, Chia KS, Matsuo K, Qiao YL, Rothman N, Zheng W, Inoue M, Kang D, and Boffetta P
- Subjects
- Humans, Incidence, Asia epidemiology, Male, Female, Adult, Middle Aged, Cohort Studies, Diabetes Mellitus epidemiology, Diabetes Mellitus mortality, Risk Factors, Proportional Hazards Models, Aged, Liver Neoplasms epidemiology, Liver Neoplasms mortality
- Abstract
There has been growing evidence suggesting that diabetes may be associated with increased liver cancer risk. However, studies conducted in Asian countries are limited. This project considered data of 968,738 adults pooled from 20 cohort studies of Asia Cohort Consortium to examine the association between baseline diabetes and liver cancer incidence and mortality. Cox proportional hazard model and competing risk approach was used for pooled data. Two-stage meta-analysis across studies was also done. There were 839,194 subjects with valid data regarding liver cancer incidence (5654 liver cancer cases [48.29/100,000 person-years]), follow-up time and baseline diabetes (44,781 with diabetes [5.3%]). There were 747,198 subjects with valid data regarding liver cancer mortality (5020 liver cancer deaths [44.03/100,000 person-years]), follow-up time and baseline diabetes (43,243 with diabetes [5.8%]). Hazard ratio (HR) (95% confidence interval [95%CI]) of liver cancer diagnosis in those with vs. without baseline diabetes was 1.97 (1.79, 2.16) (p < .0001) after adjusting for baseline age, gender, body mass index, tobacco smoking, alcohol use, and heterogeneity across studies (n = 586,072; events = 4620). Baseline diabetes was associated with increased cumulative incidence of death due to liver cancer (adjusted HR (95%CI) = 1.97 (1.79, 2.18); p < .0001) (n = 595,193; events = 4110). A two-stage meta-analytic approach showed similar results. This paper adds important population-based evidence to current literature regarding the increased incidence and mortality of liver cancer in adults with diabetes. The analysis of data pooled from 20 studies of different Asian countries and the meta-analysis across studies with large number of subjects makes the results robust., (© 2024 UICC.)
- Published
- 2024
- Full Text
- View/download PDF
41. GWAS of Folate Metabolism With Gene-environment Interaction Analysis Revealed the Possible Role of Lifestyles in the Control of Blood Folate Metabolites in Japanese: The J-MICC Study.
- Author
-
Tsukamoto M, Hishida A, Tamura T, Nagayoshi M, Okada R, Kubo Y, Kato Y, Hamajima N, Nishida Y, Shimanoe C, Ibusuki R, Shibuya K, Takashima N, Nakamura Y, Kusakabe M, Nakamura Y, Koyanagi YN, Oze I, Nishiyama T, Suzuki S, Watanabe I, Matsui D, Otonari J, Ikezaki H, Katsuura-Kamano S, Arisawa K, Kuriki K, Nakatochi M, Momozawa Y, Takeuchi K, Wakai K, and Matsuo K
- Subjects
- Humans, Japan, Male, Female, Middle Aged, Adult, Aged, Methylenetetrahydrofolate Reductase (NADPH2) genetics, Vitamin B 12 blood, Cohort Studies, Polymorphism, Single Nucleotide, East Asian People, Folic Acid blood, Genome-Wide Association Study, Gene-Environment Interaction, Homocysteine blood, Life Style
- Abstract
Background: The present genome-wide association study (GWAS) aimed to reveal the genetic loci associated with folate metabolites, as well as to detect related gene-environment interactions in Japanese., Methods: We conducted the GWAS of plasma homocysteine (Hcy), folic acid (FA), and vitamin B
12 (VB12 ) levels in the Japan Multi-Institutional Collaborative Cohort (J-MICC) Study participants who joined from 2005 to 2012, and also estimated gene-environment interactions. In the replication phase, we used data from the Yakumo Study conducted in 2009. In the discovery phase, data of 2,263 participants from four independent study sites of the J-MICC Study were analyzed. In the replication phase, data of 573 participants from the Yakumo Study were analyzed., Results: For Hcy, MTHFR locus on chr 1, NOX4 on chr 11, CHMP1A on chr 16, and DPEP1 on chr 16 reached genome-wide significance (P < 5 × 10-8 ). MTHFR also associated with FA, and FUT2 on chr 19 associated with VB12 . We investigated gene-environment interactions in both studies and found significant interactions between MTHFR C677T and ever drinking, current drinking, and physical activity >33% on Hcy (β = 0.039, 0.038 and -0.054, P = 0.018, 0.021 and <0.001, respectively) and the interaction of MTHFR C677T with ever drinking on FA (β = 0.033, P = 0.048)., Conclusion: The present GWAS revealed the folate metabolism-associated genetic loci and gene-environment interactions with drinking and physical activity in Japanese, suggesting the possibility of future personalized cardiovascular disease prevention.- Published
- 2024
- Full Text
- View/download PDF
42. Association between consumption of small fish and all-cause mortality among Japanese: the Japan Multi-Institutional Collaborative Cohort Study.
- Author
-
Kasahara C, Tamura T, Wakai K, Tamada Y, Kato Y, Kubo Y, Okada R, Nagayoshi M, Hishida A, Imaeda N, Goto C, Otonari J, Ikezaki H, Nishida Y, Shimanoe C, Oze I, Koyanagi YN, Nakamura Y, Kusakabe M, Nishimoto D, Shimoshikiryo I, Suzuki S, Watanabe M, Ozaki E, Omichi C, Kuriki K, Takashima N, Miyagawa N, Arisawa K, Katsuura-Kamano S, Takeuchi K, and Matsuo K
- Subjects
- Adult, Aged, Animals, Female, Humans, Male, Middle Aged, Cause of Death, Cohort Studies, East Asian People, Follow-Up Studies, Japan epidemiology, Mortality, Risk Factors, Diet statistics & numerical data, Fishes, Neoplasms mortality, Proportional Hazards Models, Seafood statistics & numerical data
- Abstract
Objective: Although small fish are an important source of micronutrients, the relationship between their intake and mortality remains unclear. This study aimed to clarify the association between intake of small fish and all-cause and cause-specific mortality., Design: We used the data from a cohort study in Japan. The frequency of the intake of small fish was assessed using a validated FFQ. The hazard ratio (HR) and 95 % confidence interval (CI) for all-cause and cause-specific mortality according to the frequency of the intake of small fish by sex were estimated using a Cox proportional hazard model with adjustments for covariates., Setting: The Japan Multi-Institutional Collaborative Cohort Study., Participants: A total of 80 802 participants (34 555 males and 46 247 females), aged 35-69 years., Results: During a mean follow-up of 9·0 years, we identified 2482 deaths including 1495 cancer-related deaths. The intake of small fish was statistically significantly and inversely associated with the risk of all-cause and cancer mortality in females. The multivariable-adjusted HR (95 % CI) in females for all-cause mortality according to the intake were 0·68 (0·55, 0·85) for intakes 1-3 times/month, 0·72 (0·57, 0·90) for 1-2 times/week and 0·69 (0·54, 0·88) for ≥ 3 times/week, compared with the rare intake. The corresponding HR (95 % CI) in females for cancer mortality were 0·72 (0·54, 0·96), 0·71 (0·53, 0·96) and 0·64 (0·46, 0·89), respectively. No statistically significant association was observed in males., Conclusions: Intake of small fish may reduce the risk of all-cause and cancer mortality in Japanese females.
- Published
- 2024
- Full Text
- View/download PDF
43. Impacts of probiotics on the efficacies of immune checkpoint inhibitors with or without chemotherapy for patients with advanced non-small-cell lung cancer.
- Author
-
Morita A, Ichihara E, Inoue K, Fujiwara K, Yokoyama T, Harada D, Ando C, Kano H, Oda N, Tamura T, Ochi N, Kawai H, Inoue M, Hara N, Fujimoto N, Ichikawa H, Oze I, Hotta K, Maeda Y, and Kiura K
- Subjects
- Humans, Male, Female, Immune Checkpoint Inhibitors therapeutic use, Databases, Factual, Carcinoma, Non-Small-Cell Lung drug therapy, Lung Neoplasms drug therapy, Probiotics therapeutic use
- Abstract
The relationships between the therapeutic effects of immune checkpoint inhibitors (ICIs) and the intestinal flora have attracted increasing attention. However, the effects of oral probiotics on the efficacies of ICIs used to treat non-small-cell lung cancer (NSCLC) remain unclear. We investigated the effects of probiotics on the efficacies of ICIs in patients treated with and without chemotherapy. We investigated patients with advanced NSCLC on ICI monotherapy or combination ICI and chemotherapy using the Okayama Lung Cancer Study Group Immunotherapy Database (OLCSG-ID) and the Okayama Lung Cancer Study Group Immunochemotherapy Database (OLCSG-ICD). In total, 927 patients (482 on ICI monotherapy, 445 on an ICI + chemotherapy) were enrolled. Most were male, of good performance status, smokers, and without epidermal growth factor receptor (EGFR)/anaplastic lymphoma kinase (ALK) mutations. Probiotics were administered to 19% of patients on ICI monotherapies and 17% of those on ICIs + chemotherapy. Of the former patients, progression-free survival (PFS) and overall survival (OS) were significantly better in the probiotics group (PFS 7.9 vs. 2.9 months, hazard ratio [HR] 0.54, p < .001; OS not attained vs. 13.1 months, HR 0.45, p < .001). Among patients receiving ICI and chemotherapy, there were no significant differences in PFS between those on probiotics and not but OS was significantly better in the probiotics group (PFS 8.8 vs. 8.6 months, HR 0.89, p = .43; OS not attained vs. 22.6 months, HR 0.61, p = .03). Patients on probiotics experienced better outcomes following ICI treatment., (© 2024 UICC.)
- Published
- 2024
- Full Text
- View/download PDF
44. Fine-mapping analysis including over 254,000 East Asian and European descendants identifies 136 putative colorectal cancer susceptibility genes.
- Author
-
Chen Z, Guo X, Tao R, Huyghe JR, Law PJ, Fernandez-Rozadilla C, Ping J, Jia G, Long J, Li C, Shen Q, Xie Y, Timofeeva MN, Thomas M, Schmit SL, Díez-Obrero V, Devall M, Moratalla-Navarro F, Fernandez-Tajes J, Palles C, Sherwood K, Briggs SEW, Svinti V, Donnelly K, Farrington SM, Blackmur J, Vaughan-Shaw PG, Shu XO, Lu Y, Broderick P, Studd J, Harrison TA, Conti DV, Schumacher FR, Melas M, Rennert G, Obón-Santacana M, Martín-Sánchez V, Oh JH, Kim J, Jee SH, Jung KJ, Kweon SS, Shin MH, Shin A, Ahn YO, Kim DH, Oze I, Wen W, Matsuo K, Matsuda K, Tanikawa C, Ren Z, Gao YT, Jia WH, Hopper JL, Jenkins MA, Win AK, Pai RK, Figueiredo JC, Haile RW, Gallinger S, Woods MO, Newcomb PA, Duggan D, Cheadle JP, Kaplan R, Kerr R, Kerr D, Kirac I, Böhm J, Mecklin JP, Jousilahti P, Knekt P, Aaltonen LA, Rissanen H, Pukkala E, Eriksson JG, Cajuso T, Hänninen U, Kondelin J, Palin K, Tanskanen T, Renkonen-Sinisalo L, Männistö S, Albanes D, Weinstein SJ, Ruiz-Narvaez E, Palmer JR, Buchanan DD, Platz EA, Visvanathan K, Ulrich CM, Siegel E, Brezina S, Gsur A, Campbell PT, Chang-Claude J, Hoffmeister M, Brenner H, Slattery ML, Potter JD, Tsilidis KK, Schulze MB, Gunter MJ, Murphy N, Castells A, Castellví-Bel S, Moreira L, Arndt V, Shcherbina A, Bishop DT, Giles GG, Southey MC, Idos GE, McDonnell KJ, Abu-Ful Z, Greenson JK, Shulman K, Lejbkowicz F, Offit K, Su YR, Steinfelder R, Keku TO, van Guelpen B, Hudson TJ, Hampel H, Pearlman R, Berndt SI, Hayes RB, Martinez ME, Thomas SS, Pharoah PDP, Larsson SC, Yen Y, Lenz HJ, White E, Li L, Doheny KF, Pugh E, Shelford T, Chan AT, Cruz-Correa M, Lindblom A, Hunter DJ, Joshi AD, Schafmayer C, Scacheri PC, Kundaje A, Schoen RE, Hampe J, Stadler ZK, Vodicka P, Vodickova L, Vymetalkova V, Edlund CK, Gauderman WJ, Shibata D, Toland A, Markowitz S, Kim A, Chanock SJ, van Duijnhoven F, Feskens EJM, Sakoda LC, Gago-Dominguez M, Wolk A, Pardini B, FitzGerald LM, Lee SC, Ogino S, Bien SA, Kooperberg C, Li CI, Lin Y, Prentice R, Qu C, Bézieau S, Yamaji T, Sawada N, Iwasaki M, Le Marchand L, Wu AH, Qu C, McNeil CE, Coetzee G, Hayward C, Deary IJ, Harris SE, Theodoratou E, Reid S, Walker M, Ooi LY, Lau KS, Zhao H, Hsu L, Cai Q, Dunlop MG, Gruber SB, Houlston RS, Moreno V, Casey G, Peters U, Tomlinson I, and Zheng W
- Subjects
- Humans, Exome Sequencing, Case-Control Studies, Transcriptome, Chromosome Mapping, Male, Female, East Asian People, Colorectal Neoplasms genetics, Genetic Predisposition to Disease, Genome-Wide Association Study, Asian People genetics, White People genetics, Polymorphism, Single Nucleotide, Quantitative Trait Loci
- Abstract
Genome-wide association studies (GWAS) have identified more than 200 common genetic variants independently associated with colorectal cancer (CRC) risk, but the causal variants and target genes are mostly unknown. We sought to fine-map all known CRC risk loci using GWAS data from 100,204 cases and 154,587 controls of East Asian and European ancestry. Our stepwise conditional analyses revealed 238 independent association signals of CRC risk, each with a set of credible causal variants (CCVs), of which 28 signals had a single CCV. Our cis-eQTL/mQTL and colocalization analyses using colorectal tissue-specific transcriptome and methylome data separately from 1299 and 321 individuals, along with functional genomic investigation, uncovered 136 putative CRC susceptibility genes, including 56 genes not previously reported. Analyses of single-cell RNA-seq data from colorectal tissues revealed 17 putative CRC susceptibility genes with distinct expression patterns in specific cell types. Analyses of whole exome sequencing data provided additional support for several target genes identified in this study as CRC susceptibility genes. Enrichment analyses of the 136 genes uncover pathways not previously linked to CRC risk. Our study substantially expanded association signals for CRC and provided additional insight into the biological mechanisms underlying CRC development., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
45. Active and passive smoking and breast cancer in Japan: a pooled analysis of nine population-based cohort studies.
- Author
-
Wada K, Nagata C, Utada M, Sakata R, Kimura T, Tamakoshi A, Sugawara Y, Tsuji I, Sato R, Sawada N, Tsugane S, Oze I, Ito H, Kitamura T, Koyanagi YN, Lin Y, Matsuo K, Abe SK, and Inoue M
- Subjects
- Female, Humans, Japan epidemiology, Prospective Studies, Risk Factors, Breast Neoplasms epidemiology, Breast Neoplasms etiology, Tobacco Smoke Pollution adverse effects
- Abstract
Background: Epidemiological studies have shown inconsistent results regarding the link between smoking and breast cancer risk, despite the biological plausibility of a positive association., Methods: Participants were 166 611 women from nine prospective cohort studies in Japan which launched in 1984-1994 and followed for 8-22 years. Information on smoking and secondhand smoke was obtained through self-administered baseline questionnaires. Breast cancer was defined as code C50 according to the International Classification of Diseases for Oncology, 3rd Edition or the International Classification of Diseases, 10th Revision. After adjusting for several potential confounders, relative risks for breast cancer were calculated in the individual studies according to the current or previous status of active and passive smoking using Cox regression, followed by a summary estimate of hazard ratios using random-effects meta-analyses., Results: Of the 60 441 participants who reported being premenopausal and 106 170 who reported being postmenopausal at baseline, 897 and 1168 developed breast cancer during follow-up, respectively. Compared with never smokers, current smokers had a higher risk of developing breast cancer before the age of 50 years. In addition, ever smokers who started smoking at 30 years of age or younger, or who started smoking before first childbirth, had a higher risk of developing breast cancer before the age of 50 years. No association between adulthood or childhood exposure to secondhand smoke and breast cancer was observed., Conclusion: Smoking may increase the risk of premenopausal breast cancer, and smoking earlier in life might be especially harmful. The impact of secondhand smoke needs further investigation., (© The Author(s) 2024; all rights reserved. Published by Oxford University Press on behalf of the International Epidemiological Association.)
- Published
- 2024
- Full Text
- View/download PDF
46. Obesity is associated with biliary tract cancer mortality and incidence: A pooled analysis of 21 cohort studies in the Asia Cohort Consortium.
- Author
-
Oze I, Ito H, Koyanagi YN, Abe SK, Rahman MS, Islam MR, Saito E, Gupta PC, Sawada N, Tamakoshi A, Shu XO, Sakata R, Malekzadeh R, Tsuji I, Kim J, Nagata C, You SL, Park SK, Yuan JM, Shin MH, Kweon SS, Pednekar MS, Tsugane S, Kimura T, Gao YT, Cai H, Pourshams A, Lu Y, Kanemura S, Wada K, Sugawara Y, Chen CJ, Chen Y, Shin A, Wang R, Ahn YO, Shin MH, Ahsan H, Boffetta P, Chia KS, Qiao YL, Rothman N, Zheng W, Inoue M, Kang D, and Matsuo K
- Subjects
- Male, Female, Humans, Obesity complications, Obesity epidemiology, Overweight epidemiology, Risk Factors, Cohort Studies, Asia epidemiology, Body Mass Index, Biliary Tract Neoplasms epidemiology, Cholelithiasis complications, Cholelithiasis epidemiology
- Abstract
Body fatness is considered a probable risk factor for biliary tract cancer (BTC), whereas cholelithiasis is an established factor. Nevertheless, although obesity is an established risk factor for cholelithiasis, previous studies of the association of body mass index (BMI) and BTC did not take the effect of cholelithiasis fully into account. To better understand the effect of BMI on BTC, we conducted a pooled analysis using population-based cohort studies in Asians. In total, 905 530 subjects from 21 cohort studies participating in the Asia Cohort Consortium were included. BMI was categorized into four groups: underweight (<18.5 kg/m
2 ); normal (18.5-22.9 kg/m2 ); overweight (23-24.9 kg/m2 ); and obese (25+ kg/m2 ). The association between BMI and BTC incidence and mortality was assessed using hazard ratios (HR) and 95% confidence intervals (CIs) by Cox regression models with shared frailty. Mediation analysis was used to decompose the association into a direct and an indirect (mediated) effect. Compared to normal BMI, high BMI was associated with BTC mortality (HR 1.19 [CI 1.02-1.38] for males, HR 1.30 [1.14-1.49] for females). Cholelithiasis had significant interaction with BMI on BTC risk. BMI was associated with BTC risk directly and through cholelithiasis in females, whereas the association was unclear in males. When cholelithiasis was present, BMI was not associated with BTC death in either males or females. BMI was associated with BTC death among females without cholelithiasis. This study suggests BMI is associated with BTC mortality in Asians. Cholelithiasis appears to contribute to the association; and moreover, obesity appears to increase BTC risk without cholelithiasis., (© 2023 UICC.)- Published
- 2024
- Full Text
- View/download PDF
47. Body mass index and lung cancer risk: Pooled analysis of 10 prospective cohort studies in Japan.
- Author
-
Kawai S, Lin Y, Tsuge H, Ito H, Matsuo K, Wada K, Nagata C, Narii N, Kitamura T, Utada M, Sakata R, Kimura T, Tamakoshi A, Sugawara Y, Tsuji I, Suzuki S, Sawada N, Tsugane S, Mizoue T, Oze I, Abe SK, and Inoue M
- Subjects
- Humans, Male, Female, Body Mass Index, Japan epidemiology, Risk Factors, Prospective Studies, Obesity complications, Obesity epidemiology, Proportional Hazards Models, Lung Neoplasms etiology, Lung Neoplasms complications
- Abstract
Mounting evidence suggests that body mass index (BMI) is inversely associated with the risk of lung cancer. However, relatively few studies have explored this association in Asian people, who have a much lower prevalence of obesity than Caucasians. We pooled data from 10 prospective cohort studies involving 444,143 Japanese men and women to address the association between BMI and the risk of lung cancer. Study-specific hazard ratios (HRs) and 95% confidence intervals (CIs) were calculated in each cohort using the Cox proportional hazards model. A meta-analysis was undertaken by combining the results from each cohort. Heterogeneity across studies was evaluated using Cochran's Q and I
2 statistics. During 5,730,013 person-years of follow-up, 6454 incident lung cancer cases (4727 men and 1727 women) were identified. Baseline BMI was inversely associated with lung cancer risk in men and women combined. While leanness (BMI <18.5) was associated with a higher risk of lung cancer (HR 1.35; 95% CI, 1.16-1.57), overweight and obesity were associated with a lower risk, with HRs of 0.77 (95% CI, 0.71-0.84) and 0.69 (95% CI, 0.45-1.07), respectively. Every 5 kg/m2 increase in BMI was associated with a 21% lower risk of lung cancer (HR 0.79; 95% CI, 0.75-0.83; p < 0.0001). Our pooled analysis indicated that BMI is inversely associated with the risk of lung cancer in the Japanese population. This inverse association could be partly attributed to residual confounding by smoking, as it was more pronounced among male smokers., (© 2024 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association.)- Published
- 2024
- Full Text
- View/download PDF
48. Confounding in epidemiological studies on assessment of the impact of genetic factors on disease risk: the problem of redundant adjustment.
- Author
-
Kasugai Y, Oze I, Koyanagi YN, Taniyama Y, Ito H, Imoto I, and Matsuo K
- Published
- 2024
- Full Text
- View/download PDF
49. Chronological improvement of survival in patients with advanced gastric cancer over 15 years.
- Author
-
Ogata T, Narita Y, Oze I, Kumanishi R, Nakazawa T, Matsubara Y, Kodama H, Nakata A, Honda K, Masuishi T, Bando H, Taniguchi H, Kadowaki S, Ando M, Ito S, Tajika M, and Muro K
- Abstract
Background: Recent trials have reported a median overall survival (OS) of 11-17 months in patients with advanced gastric cancer (AGC). However, it is unclear how recently approved drugs contribute to patient prognosis., Objectives: We aimed to evaluate the characteristics and survival in patients with AGC over the past 15 years., Design: Retrospective study., Methods: We evaluated data of 1355 patients with AGC who received first-line chemotherapy between January 2005 and March 2019 at a single institution. We compared the characteristics and survival rates across four periods: January 2005-December 2007 (period A), January 2008-February 2011 (period B), March 2011-May 2015 (period C), and June 2015-March 2019 (period D). The median follow-up duration was 13.1 months, with 312, 333, 393, and 317 patients in periods A, B, C, and D, respectively., Results: There were no significant differences in patient characteristics between the four periods, except for the proportion of patients who underwent prior gastrectomy and human epidermal growth factor receptor 2 (HER2) testing. Patients in period D had significantly longer OS than those in period A [median: 15.7 versus 12.4 months; adjusted hazard ratio (aHR): 0.79; p = 0.02]. The mean OS in patients with liver metastasis (LM) in period D was remarkably longer than that in patients in period A (median: 19.3 versus 12.4 months; aHR: 0.61; p < 0.01), while that in patients with peritoneal metastasis showed limited improvement., Conclusion: Clinical strategy changes, including gastrectomy, HER2 testing, and approval of new drugs, may be associated with improved OS in patients with AGC. In the last 4 years, a remarkable improvement has been observed in patients with LM., Competing Interests: TO reports personal fees from ONO Pharmaceutical, personal fees from BMS, personal fees from Taiho, personal fees from Daichi-Sankyo, outside the submitted work; YN reports grants and personal fees from ONO Pharmaceutical, grants and personal fees from Bristol-Mayers Squibb, grants and personal fees from AstraZeneca, grants and personal fees from Daiichi Sankyo, grants and personal fees from Yakult Honsha, personal fees from Taiho, personal fees from Eli Lilly, outside the submitted work; YM reports personal fees from MSD, personal fees from Lilly Japan, personal fees from Takeda, personal fees from Bristol Myers Squibb, personal fees from Taiho, outside the submitted work; KH reports grants from Pfizer, outside the submitted work; TM reports grants and personal fees from MSD, grants and personal fees from Amgen, grants and personal fees from ONO Pharmaceutical, grants and personal fees from Daiichi Sankyo, grants from Novartis, grants from Pfizer, personal fees from Taiho, personal fees from Bristol Myers Squibb, personal fees from Eli Lilly, personal fees from Takeda, grants from Boehringer-Ingelheim, grants from Syneos Health Clinical, personal fees from Chugai, personal fees from Nippon Kayaku, grants from Cimic Shift Zero, personal fees from Merck Bio Pharma, personal fees from Bayer, personal fees from Yakult Honsha, personal fees from Sanofi, personal fees from ONO Pharmaceutical, outside the submitted work; HT reports grants and personal fees from Takeda, grants from Daiichi Sankyo, grants and personal fees from ONO Pharmaceutical, personal fees from Eli Lilly, personal fees from Merck Biopharma, personal fees from Chugai, outside the submitted work; SK reports grants and personal fees from Eli Lilly, grants from Nobelpharma, grants and personal fees from Taiho, grants and personal fees from MSD, grants and personal fees from Bayer, grants from Yansen, grants and personal fees from Chugai, grants and personal fees from ONO Pharmaceutical, grants from Daiichi Sankyo, personal fees from Merck, personal fees from BMS, outside the submitted work; MA reports personal fees from Eisai Co., Ltd, personal fees from ONO Pharmaceutical, personal fees from Chugai Pharmaceutical Co. Ltd, personal fees from Mundipharma Co., Ltd, personal fees from Taiho Pharmaceutical Co., Ltd, outside the submitted work; SI reports grants from ONO Pharmaceutical, grants from Merck Sharp & Dohme, grants from AstraZeneca, personal fees from Taiho Pharmaceutical, personal fees from Otsuka, outside the submitted work; MT reports personal fees from Bristol Myers Squibb, outside the submitted work; KM reports grants from Chugai, grants and personal fees from MSD, grants and personal fees from Amgen, grants and personal fees from ONO Pharmaceutical, grants from Astellas, grants from Sanofi, grants from Taiho, grants from Eisai, grants and personal fees from Daiichi Sankyo, grants from Novartis, grants from Pfizer, personal fees from AstraZeneca, personal fees from Taiho, personal fees from Bristol Myers Squibb, personal fees from Eli Lilly, personal fees from Takeda, outside the submitted work; others have declared no potential conflicts of interest., (© The Author(s), 2024.)
- Published
- 2024
- Full Text
- View/download PDF
50. BMI and Cardiometabolic Traits in Japanese: A Mendelian Randomization Study.
- Author
-
Nagayoshi M, Hishida A, Shimizu T, Kato Y, Kubo Y, Okada R, Tamura T, Otonari J, Ikezaki H, Hara M, Nishida Y, Oze I, Koyanagi YN, Nakamura Y, Kusakabe M, Ibusuki R, Shibuya K, Suzuki S, Nishiyama T, Koyama T, Ozaki E, Kuriki K, Takashima N, Nakamura Y, Katsuura-Kamano S, Arisawa K, Nakatochi M, Momozawa Y, Takeuchi K, and Wakai K
- Subjects
- Humans, Body Mass Index, Japan epidemiology, Cohort Studies, Genome-Wide Association Study, Mendelian Randomization Analysis, Obesity epidemiology, Obesity genetics, Polymorphism, Single Nucleotide, Diabetes Mellitus, Type 2 epidemiology, Diabetes Mellitus, Type 2 genetics, Hypertension
- Abstract
Background: Although many observational studies have demonstrated significant relationships between obesity and cardiometabolic traits, the causality of these relationships in East Asians remains to be elucidated., Methods: We conducted individual-level Mendelian randomization (MR) analyses targeting 14,083 participants in the Japan Multi-Institutional Collaborative Cohort Study and two-sample MR analyses using summary statistics based on genome-wide association study data from 173,430 Japanese. Using 83 body mass index (BMI)-related loci, genetic risk scores (GRS) for BMI were calculated, and the effects of BMI on cardiometabolic traits were examined for individual-level MR analyses using the two-stage least squares estimator method. The β-coefficients and standard errors for the per-allele association of each single-nucleotide polymorphism as well as all outcomes, or odds ratios with 95% confidence intervals were calculated in the two-sample MR analyses., Results: In individual-level MR analyses, the GRS of BMI was not significantly associated with any cardiometabolic traits. In two-sample MR analyses, higher BMI was associated with increased risks of higher blood pressure, triglycerides, and uric acid, as well as lower high-density-lipoprotein cholesterol and eGFR. The associations of BMI with type 2 diabetes in two-sample MR analyses were inconsistent using different methods, including the directions., Conclusion: The results of this study suggest that, even among the Japanese, an East Asian population with low levels of obesity, higher BMI could be causally associated with the development of a variety of cardiometabolic traits. Causality in those associations should be clarified in future studies with larger populations, especially those of BMI with type 2 diabetes.
- Published
- 2024
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.